ReviewBlood advances2025
Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions.
Review in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractMicroRNAs (miRNAs) are essential regulators of hematopoiesis, influencing stem cell maintenance, lineage specification, and differentiation. While their dysregulation has been widely implicated in hematological malignancies such as acute myeloid leukemia, progress toward clinical translation has been hindered by methodological inconsistencies, oversimplified interpretations, and model limitations. This viewpoint discusses the context-dependent nature of miRNA-mRNA interactions, the influence of isomiRs, and the impact of RNA-binding proteins and epitranscriptomic modifications on miRNA activity. We highlight the limitations of commonly used bulk sequencing and reductionist models, and advocate for more physiologically relevant systems, including hematopoietic organoids, single-cell and spatial transcriptomics, and CRISPR-based functional assays. Furthermore, we discuss advances in miRNA-targeted therapeutics, such as lipid nanoparticle delivery and anti-miRs. By integrating emerging technologies with standardized methodologies and biological complexity, miRNA research in hematology will uncover new regulatory mechanisms and therapeutic vulnerabilities, offering a robust path toward diagnostic, prognostic, and treatment applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.